Key result
Bromocriptine added to standard therapy improves LVEF by ~15% in peripartum cardiomyopathy.
Why the study?
Peripartum cardiomyopathy causes significant maternal morbidity and mortality with incomplete recovery in many patients, prompting evaluation of whether adding bromocriptine to standard heart failure therapy improves left ventricular recovery and cardiovascular mortality.
Does bromocriptine added to standard heart failure therapy improve left ventricular ejection fraction and reduce cardiovascular mortality in patients with peripartum cardiomyopathy?
Meta-Analysis (n=116)
Yes
Does bromocriptine added to standard heart failure therapy improve left ventricular ejection fraction and reduce cardiovascular mortality in patients with peripartum cardiomyopathy?
Effect estimate: Mean difference 15.14% (95% CI 6.53 to 23.75)
p-value: p=0.0006
The addition of bromocriptine to standard heart failure therapy significantly improves left ventricular ejection fraction recovery at 6 months in women with peripartum cardiomyopathy.
May support bromocriptine addition for LVEF recovery in peripartum cardiomyopathy; confirms benefit in Level 1 meta-analysis.
Peripartum cardiomyopathy is a rare, pregnancy associated cause of left ventricular heart failure in previously healthy women. It remains an important cause of cardiac-related maternal morbidity and mortality worldwide. Half of the patients will recover left ventricular function after 6 months. However, in the remainder of patients who do not recover cardiac function, they will require advanced heart failure therapies. Bromocriptine, a dopamine agonist which inhibits prolactin release, has demonstrated improvement in left ventricular recovery and clinical outcome. We sought to determine the effect of adding Bromocriptine to standard heart failure therapy on the improvement and recovery of left ventricular function and cardiovascular mortality of these patients.
No takes yet. Share an insight, caveat, or question.
E et al. (2020) conducted a meta-analysis in Peripartum cardiomyopathy (n=116). Bromocriptine + standard heart failure therapy vs. Standard heart failure therapy alone was evaluated on Improvement in left ventricular ejection fraction at 6 months (Mean difference 15.14%, 95% CI 6.53 to 23.75, p=0.0006). The addition of bromocriptine to standard heart failure therapy significantly improved left ventricular ejection fraction by a mean difference of 15.14% at 6 months in patients with peripartum cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: